PolyNovo trade agreed

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Xceed Capital [ASX: XCD] has agreed to sell its 64 per cent stake in PolyNovo Biomaterials to Metabolic Pharmaceuticals [ASX: MBP].

The sale has been on the cards for some time, but both parties have finally signed off on the deal.

Under the arrangement Xceed, an investment company, will trade Metabolic its stake in return for 1.5 MBP shares for every PolyNovo share Xceed owns.

The deal must still be approved by both Xceed and Metabolic shareholders. Xceed is holding a shareholder's meeting to discuss the sale in November.

Related News

Sleep apnoea patients who use CPAP live longer: study

CPAP therapy has been found to significantly reduce the risk of death for people with obstructive...

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd